| Cas No.: | 1644545-52-7 |
| Chemical Name: | Vorasidenib |
| Synonyms: | Vorasidenib;AG881;789Q85GA8P;6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoropropan-2-yl)-1,3,5-triazine-2,4-diamine;6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine;9UO;Vorasidenib [INN];Vorasidenib [USAN];Vorasidenib (AG881);Vorasidenib (USAN/INN);AG 881 [WHO-DD];GTPL10663;BDBM279948;NSC803600;s8611;US10028961, C |
| SMILES: | ClC1=C([H])C([H])=C([H])C(C2=NC(=NC(=N2)N([H])[C@]([H])(C([H])([H])[H])C(F)(F)F)N([H])[C@]([H])(C([H])([H])[H])C(F)(F)F)=N1 |
| Formula: | C14H13ClF6N6 |
| M.Wt: | 414.7366 |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Vorasidenib is a pan isocitrate dehydrogenase (IDH) inhibitor. |
| In Vitro: | Vorasidenib has recently entered phase 1 clinical trials in hematologic (NCT02492737) and solid malignancies (NCT02481154) in patients with either an IDH1 or an IDH2 mutation. Preclinical studies have suggested that Vorasidenib fully penetrates the blood-brain barrier and may be a more effective option for patients with IDH1/2 mutated glioma[1]. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|